RxDoctor Payments Data

Christopher Finnegan, PA

Medical · Huntington, NYNPI 1275597213

Payments from drug & device makers

$1,352in general payments, 2019–2025

Across 62 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$566
  • Gilead$459
  • Lundbeck LLC$126
  • Corium, LLC$61
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$39
  • Otsuka America Pharmaceutical, Inc.$28
  • plus $74 from 4 others

What the payments were for

  • Food & beverage$1,352100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,352 in reported general payments places this provider in the 70th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$66,845
Medicare patients
525
Services billed
931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate49$29,083
EntrestoSacubitril/Valsartan12$8,682
VascepaIcosapent Ethyl19$6,814
Lagevrio (Eua)Molnupiravir11$3,674
Bethanechol Chloride25$2,529
Albuterol Sulfate HfaAlbuterol Sulfate106$2,506
CreonLipase/Protease/Amylase12$2,470
Rosuvastatin Calcium31$2,408
Niacin ErNiacin13$1,879
Repaglinide13$1,847
Mesalamine ErMesalamine12$1,505
Tamsulosin Hcl50$1,495
Ezetimibe-SimvastatinEzetimibe/Simvastatin13$1,093
Nateglinide18$837
Gabapentin67$813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$566$2,47012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,395 medical providers in New York.

Other medical in Huntington

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →